Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CStone Pharmaceuticals

Request full access

Biopharmaceutical company developing and commercializing oncology and precision medicines

Pudong, ChinaFounded 2015Biotech & Life Sciences

About CStone Pharmaceuticals

CStone Pharmaceuticals (HKEX: 2616) is a Chinese biopharmaceutical company focused on the development and commercialization of innovative oncology and precision medicines. Founded in late 2015 and headquartered in Shanghai, the company builds its portfolio around immuno-oncology assets and precision oncology therapies targeting cancers with high unmet medical need in China and globally.

The company has launched four innovative medicines and secured 21 new drug application approvals covering nine indications. Its marketed products include sugemalimab (CEJEMLY), an anti-PD-L1 antibody approved for non-small cell lung cancer indications, including marketing authorizations in the European Union and the United Kingdom; pralsetinib (GAVRETO), a RET inhibitor; and avapritinib (AYVAKIT), a KIT/PDGFRA inhibitor for gastrointestinal stromal tumors, with China National Reimbursement Drug List inclusions supporting patient access.

CStone's Pipeline 2.0 advances more than nine candidates spanning multispecific antibodies and antibody-drug conjugates, led by CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody in Phase I/II clinical development, and CS5001, an anti-ROR1 antibody-drug conjugate. The company operates an in-house ADC technology platform and a Translational Medicine Research Center in Suzhou. Revenue comes from product sales, licensing and partnership income, with commercialization partnerships extending sugemalimab's reach to more than 60 countries across Europe, the Middle East, North Africa and Latin America.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019

CStone Pharmaceuticals in the Pudong ecosystem

Live from Dealroom

The CStone Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A12 investors entered at this stage

Series B and later9 investors entered at this stage

Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$46M

23 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See CStone Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.